A summertime pause in immunoglobulin replacement therapy: a prospective real-world analysis

Area of Science:

• Immunology
• Clinical Medicine
• Pharmacology

Background:

• Immunoglobulin replacement therapy (IgRT) is crucial for primary and secondary immunodeficiencies.
• A summertime pause (SP) in IgRT is sometimes considered but its effects require further investigation.
• Understanding the impact of SP is essential for optimizing patient management and resource allocation.

Purpose of the Study:

• To evaluate the safety and efficacy of a summertime pause (SP) in intravenous immunoglobulin replacement therapy (IgRT).
• To assess the impact of SP on infection rates, quality of life, and treatment costs.
• To identify patient subgroups who may benefit from an SP in IgRT.

Main Methods:

• Prospective, single-center observational study.
• Inclusion of 44 patients receiving intravenous IgRT between May and June 2019.
• Comparison of outcomes between patients who underwent an SP (n=23) and those who did not.

Main Results:

• Patients undergoing SP were older, had higher rates of secondary immunodeficiency (SID), and received lower immunoglobulin doses and more winter antibiotics.
• No increased risk of infection was observed in patients who took an SP.
• Quality of life improved, and treatment costs were reduced with an SP.
• Patients not taking an SP predominantly had severe primary immunodeficiency.

Conclusions:

• Summertime pauses in IgRT are a safe strategy for patients with mild secondary immunodeficiency.
• SP in IgRT can lead to improved quality of life and cost savings.
• Consideration of SP in IgRT management is recommended for eligible patients with mild SID.